A safety study of Lutathera in newly diagnosed glioblastoma patients in combination with currently approved treatments or in patients with recurrent glioblastoma as a single agent.
Zusammenfassung der Studie
Glioblastoma (GB) is the most common malignant tumor of the central nervous system. Given the available data, GB could be a plausible target for targeted peptide receptor radionuclide therapy, Lutathera. Lutathera was approved in 2019 for the treatment of inoperable or metastatic, progressive gastroenteropancreatic neuroendocrine tumors (NET) with sufficient expression of somatostatin receptors on tumor cells in adults. A radioactive particle (Lutetium-177) is used, which is attached to a targeting ligand that specifically binds to somatostatin receptors (receptors for the hormone somatostatin) on the surface of tumor cells. Due to the presence of somatostatin receptors in GB samples, Lutathera could broadly irradiate tumor margins. This open-label, multicenter study aims to determine the recommended dose of Lutathera® in combination with standard treatment or as a single agent in three different groups of participants with glioblastoma. Eligible participants with newly diagnosed glioblastoma will be assigned to group 1 or group 2 based on the amounts of a form of biomarker (laboratory value of the MGMT biomarker). Participants with recurrent glioblastoma will be assigned to group 3. Furthermore, this study will investigate the safety of Netspot® as an imaging agent in participants with glioblastoma. Netspot® is already approved for imaging somatostatin receptors on NET cells using positron emission tomography (PET).
(BASEC)
Untersuchte Intervention
- All participants will be scanned during screening with Netspot® PET/CT (or PET/MRI) to check if we can use this examination as a new imaging method in patients with GB. - Participants in group 1 will receive treatment with Lutathera® in combination with standard treatment. Lutathera® will be administered in the nuclear medicine department every 4 weeks up to a total of 6 times. Radiation therapy and temozolomide will be administered 7 to 10 days after the first administration of Lutathera®. Radiation therapy will be conducted 5 days a week, followed by 2 rest days, over 6 consecutive weeks. Temozolomide will be administered orally, concurrently with radiation therapy. During the maintenance phase, the dosage of temozolomide may be increased. - Participants in group 2 will receive treatment with Lutathera® in combination with standard therapy. Lutathera® will be administered in the nuclear medicine department every 4 weeks for the first 3 doses, then every 3 weeks as a single agent, for a total of up to 6 times. Radiation therapy will be initiated 7 to 10 days after the first administration of Lutathera® and will be conducted with a dose of 2 Gy/day for 5 days a week, followed by 2 rest days, over 6 consecutive weeks. - Participants in group 3 will receive Lutathera® every 3 weeks as a single agent.
(BASEC)
Untersuchte Krankheit(en)
Recurrent and newly diagnosed glioblastoma (brain tumor)
(BASEC)
Common criteria: - Histologically confirmed glioblastoma - Appropriate blood values of bone marrow, electrolytes, and organ functions Newly diagnosed glioblastoma: - Presence of a gadolinium-enhanced tumor on MRI prior to surgery - Karnofsky performance status ≥ 70%. - Presence of representative tumor tissue for GB from a definitive surgery or biopsy Recurrent glioblastoma: - The participant has a first or second recurrence of their glioblastoma after standard or experimental therapy that includes prior radiation therapy. - Netspot® signal in the PET/CT or PET/MRI scan in the tumor region - Karnofsky performance status ≥ 60%. (BASEC)
Ausschlusskriterien
Common criteria: - The participant is receiving additional, concurrent active therapy for glioblastoma outside of the study - Extensive leptomeningeal disease - History of another active malignant disease in the last 3 years prior to study initiation Newly diagnosed glioblastoma: - Any prior treatment of a glioma of any grade Recurrent glioblastoma: - Early progression of disease before 3 months after completion of radiation therapy - More than 2 prior systemic therapies - Prior treatment with Bevacizumab (BASEC)
Studienstandort
Lausanne, Zürich
(BASEC)
Sponsor
Novartis Pharma Schweiz AG
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Medizinische Auskünfte
+41 41 763 71 11
swiss.medinfo@clutternovartis.comNovartis Pharma Schweiz AG Medical Information
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Zürich
(BASEC)
Datum der Bewilligung durch die Ethikkommission
28.06.2022
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Radiotherapy with or without Temozolomide and in Recurrent Glioblastoma as Single Agent (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar